trending Market Intelligence /marketintelligence/en/news-insights/trending/yuWzvMmXeYRPEp__-yta9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Novo Nordisk blockbuster diabetes drug Ozempic wins FDA nod for expanded use

Novo Nordisk A/S said the U.S. Food and Drug Administration approved a label expansion for the company's blockbuster diabetes drug Ozempic.

The U.S. regulator granted the label expansion to the injectable drug for reducing the risk of major adverse cardiovascular events — including cardiovascular death, nonfatal heart attack or nonfatal stroke — in adults with type 2 diabetes and established cardiovascular disease.

The approval was supported by results of a phase 3 trial called Sustain 6, in which Ozempic reduced the risk of major adverse heart events by 21% compared to placebo, according to a Jan. 16 news release.

The U.S. FDA first approved Ozempic in 2017 to improve glycemic control in adults with type 2 diabetes. Ozempic is also approved in the EU and Japan, among other territories.

SNL Image